BRIACELL THERAPEUTICS CORP. Income (Loss) from Equity Method Investments
BRIACELL THERAPEUTICS CORP. (BCTX) reported Income (Loss) from Equity Method Investments of -$64.30 thousand for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. income (loss) from equity method investments for the quarter ending 2026-04-30 was -$64.30K.
- BRIACELL THERAPEUTICS CORP. income (loss) from equity method investments for the quarter ending 2026-01-31 was -$61.99K.
- BRIACELL THERAPEUTICS CORP. income (loss) from equity method investments for the quarter ending 2025-10-31 was -$44.83K.
- BRIACELL THERAPEUTICS CORP. income (loss) from equity method investments for the quarter ending 2025-07-31 was -$47.38K.
- BRIACELL THERAPEUTICS CORP. income (loss) from equity method investments for fiscal 2025 was -$224.21K.
- BRIACELL THERAPEUTICS CORP. income (loss) from equity method investments for fiscal 2024 was -$106.51K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-04-30 | -$64.30K 10-Q · filed 2026-06-09 | -$126.30K derived: sum of 2 quarters · filed 2026-06-09 | -$171.13K 10-Q · filed 2026-06-09 | -$218.50K derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | -$61.99K 10-Q · filed 2026-03-10 | -$106.82K 10-Q · filed 2026-03-10 | -$154.20K derived: sum of 3 quarters · filed 2026-03-10 | -$216.94K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | -$44.83K 10-Q · filed 2025-12-11 | -$92.20K derived: sum of 2 quarters · filed 2025-12-11 | -$154.94K derived: sum of 3 quarters · filed 2026-06-09 | -$197.53K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | -$47.38K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$110.11K derived: sum of 2 quarters · filed 2026-06-09 | -$152.70K derived: sum of 3 quarters · filed 2026-06-09 | -$224.21K 10-K · filed 2025-10-16 |
| 2025-04-30 | -$62.74K 10-Q · filed 2026-06-09 | -$105.32K derived: sum of 2 quarters · filed 2026-06-09 | -$176.84K 10-Q · filed 2026-06-09 | -$228.00K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | -$42.58K 10-Q · filed 2026-03-10 | -$114.10K 10-Q · filed 2026-03-10 | -$165.27K derived: sum of 3 quarters · filed 2026-03-10 | -$202.26K derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | -$71.52K 10-Q · filed 2025-12-11 | -$122.68K derived: sum of 2 quarters · filed 2025-12-11 | -$159.68K derived: sum of 3 quarters · filed 2025-12-11 | -$178.03K derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | -$51.17K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$88.17K derived: sum of 2 quarters · filed 2025-10-16 | -$106.51K derived: sum of 3 quarters · filed 2025-10-16 | -$106.51K 10-K · filed 2025-10-16 |
| 2024-04-30 | -$37.00K 10-Q · filed 2025-06-16 | -$55.34K derived: sum of 2 quarters · filed 2025-06-16 | -$55.34K 10-Q · filed 2025-06-16 | |
| 2024-01-31 | -$18.34K 10-Q · filed 2025-03-12 | -$18.34K 10-Q · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |